Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648 [0.03%]
纳武利尤单抗联合化疗或易普利姆玛对比化疗一线治疗晚期食管鳞癌的5年随访结果（CheckMate 648）
K Kato,J Ajani,Y Doki et al.
K Kato et al.
Background: Nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit compared with chemotherapy for patients with previously untreated advanced esophageal squam...
SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation [0.03%]
III期SKYSCRAPER-03研究：含铂同步放化疗后的不可切除的局部晚期III期NSCLC患者中Tiragolumab联合Atezolizumab对比Durvalumab
H A Wakelee,M-J Ahn,J Bradley et al.
H A Wakelee et al.
Background: SKYSCRAPER-03 (NCT04513925) was a phase III, open-label, randomized, study that evaluated consolidation therapy with tiragolumab plus atezolizumab versus durvalumab in patients with locally advanced, unresecta...
Towards the practical use of AI: a tool for scalable colorectal cancer screening [0.03%]
迈向实用的AI：一种结直肠癌筛查工具
E Y T Wong,A Plumb,K K Shiu
E Y T Wong
Reply to Next-Generation Sequencing Consensus Guidelines for Sarcoma: Progress, Gaps, and the Path Forward [0.03%]
关于肉瘤下一代测序共识指南的回信：进展、差距及未来方向
C Serrano,J Y Blay,J V M G Bovée
C Serrano
A Multimodal Deep Learning Model for Preoperative Prediction of Postoperative Complications in Gastric Cancer [0.03%]
一种用于术前预测胃癌术后并发症的多模态深度学习模型
P A Ding,S Yang,L J Meng et al.
P A Ding et al.
Background: Clavien-Dindo (CD) grade ≥II complications occur in roughly one in five patients after curative gastrectomy for gastric cancer and independently shorten overall survival (OS) by compromising adjuvant therapy ...
Keeping the story, turning the page: from prognostic to predictive AI in high-risk prostate cancer [0.03%]
延续故事，翻页而行：高危前列腺癌领域的预测型人工智能取代预后型指日可待
Svenja Pascale Mende,Sebastian Foersch
Svenja Pascale Mende
Measurement of Ovarian Reserve to Tailor Systemic Therapy Decisions: Future Potential or Ready for Primetime? [0.03%]
测量卵巢储备以定制全身治疗决策：未来潜力还是准备就绪？
C Valenza,A H Partridge
C Valenza
HER2-directed TAC T cells in solid tumors: a step forward, but not yet a therapeutic leap [0.03%]
针对实体瘤的HER2导向TAC T细胞：向前迈出了一步，但尚未实现治疗突破
M Pedregal,V Moreno
M Pedregal
Jean-Yves Blay,David Perol
Jean-Yves Blay
Anjali Rohatgi,Ramaswamy Govindan
Anjali Rohatgi